SG11202007054VA - Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof - Google Patents
Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereofInfo
- Publication number
- SG11202007054VA SG11202007054VA SG11202007054VA SG11202007054VA SG11202007054VA SG 11202007054V A SG11202007054V A SG 11202007054VA SG 11202007054V A SG11202007054V A SG 11202007054VA SG 11202007054V A SG11202007054V A SG 11202007054VA SG 11202007054V A SG11202007054V A SG 11202007054VA
- Authority
- SG
- Singapore
- Prior art keywords
- solution
- pharmaceutically acceptable
- acceptable salt
- eye drops
- benzopyran derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Food Science & Technology (AREA)
- Mechanical Engineering (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180024470A KR102478553B1 (en) | 2018-02-28 | 2018-02-28 | Eye drop formulation in a solution form comprising a benzopyran derivative or pharmaceutically acceptable salt therof |
| PCT/KR2019/001894 WO2019168289A1 (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007054VA true SG11202007054VA (en) | 2020-08-28 |
Family
ID=67805843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007054VA SG11202007054VA (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11771647B2 (en) |
| EP (1) | EP3760188B1 (en) |
| JP (1) | JP7160934B2 (en) |
| KR (1) | KR102478553B1 (en) |
| CN (1) | CN111801094B (en) |
| AU (1) | AU2019226830B2 (en) |
| BR (1) | BR112020017497A2 (en) |
| CA (1) | CA3089091A1 (en) |
| ES (1) | ES2953040T3 (en) |
| MX (1) | MX2020008699A (en) |
| PH (1) | PH12020551194A1 (en) |
| SG (1) | SG11202007054VA (en) |
| WO (1) | WO2019168289A1 (en) |
| ZA (1) | ZA202005891B (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL179534B1 (en) | 1994-03-15 | 2000-09-29 | Senju Pharma Co | Method of stabilising pranoprophene and stable liquid pranoprophene preparation |
| JPH10236951A (en) * | 1996-12-27 | 1998-09-08 | Teika Seiyaku Kk | Eye drop containing pranoprofen formulated therein |
| TW546151B (en) | 1997-07-23 | 2003-08-11 | Senju Pharma Co | Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative |
| US8889112B2 (en) * | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| KR100492252B1 (en) * | 2002-08-09 | 2005-05-30 | 한국화학연구원 | Benzopyran derivatives substituted with secondary amines including imidazole and their preparation |
| JP2011011984A (en) * | 2009-06-30 | 2011-01-20 | Lion Corp | Therapeutic agent for pseudomyopia |
| US20140018402A1 (en) * | 2011-03-30 | 2014-01-16 | Catholic University Industry Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating macular degeneration |
| JP6366598B2 (en) * | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | Methods, compositions, and kits for treating, modulating, or preventing angiogenesis or fibrosis in a subject's eye using a galectin protein inhibitor |
| US9795560B2 (en) * | 2013-02-01 | 2017-10-24 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
-
2018
- 2018-02-28 KR KR1020180024470A patent/KR102478553B1/en active IP Right Grant
-
2019
- 2019-02-18 MX MX2020008699A patent/MX2020008699A/en unknown
- 2019-02-18 EP EP19760870.6A patent/EP3760188B1/en active Active
- 2019-02-18 ES ES19760870T patent/ES2953040T3/en active Active
- 2019-02-18 WO PCT/KR2019/001894 patent/WO2019168289A1/en active Application Filing
- 2019-02-18 JP JP2020545255A patent/JP7160934B2/en active Active
- 2019-02-18 BR BR112020017497-1A patent/BR112020017497A2/en unknown
- 2019-02-18 SG SG11202007054VA patent/SG11202007054VA/en unknown
- 2019-02-18 AU AU2019226830A patent/AU2019226830B2/en active Active
- 2019-02-18 CN CN201980015549.9A patent/CN111801094B/en active Active
- 2019-02-18 CA CA3089091A patent/CA3089091A1/en active Pending
- 2019-02-18 US US16/975,695 patent/US11771647B2/en active Active
-
2020
- 2020-08-06 PH PH12020551194A patent/PH12020551194A1/en unknown
- 2020-09-23 ZA ZA2020/05891A patent/ZA202005891B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3760188B1 (en) | 2023-06-14 |
| ZA202005891B (en) | 2022-03-30 |
| CA3089091A1 (en) | 2019-02-18 |
| CN111801094B (en) | 2022-11-18 |
| AU2019226830B2 (en) | 2024-01-11 |
| EP3760188A1 (en) | 2021-01-06 |
| JP2021514995A (en) | 2021-06-17 |
| PH12020551194A1 (en) | 2021-08-16 |
| EP3760188A4 (en) | 2021-10-20 |
| AU2019226830A1 (en) | 2020-08-13 |
| US20200405634A1 (en) | 2020-12-31 |
| RU2020125724A3 (en) | 2022-04-29 |
| KR20190103710A (en) | 2019-09-05 |
| KR102478553B1 (en) | 2022-12-16 |
| JP7160934B2 (en) | 2022-10-25 |
| US11771647B2 (en) | 2023-10-03 |
| EP3760188C0 (en) | 2023-06-14 |
| CN111801094A (en) | 2020-10-20 |
| RU2020125724A (en) | 2022-03-28 |
| WO2019168289A1 (en) | 2019-09-06 |
| MX2020008699A (en) | 2020-09-25 |
| ES2953040T3 (en) | 2023-11-07 |
| BR112020017497A2 (en) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276016B (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| EP3309146A4 (en) | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | |
| GB2568579B (en) | Ophthalmic drug compositions | |
| IL256339B (en) | Pyrazole derivative or pharmaceutically acceptable salt thereof | |
| PT3640239T (en) | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of derivative thereof and method for preparing same | |
| IL282504A (en) | Ocular formulations for drug-delivery and protection of the anterior segment of the eye | |
| EP3725780A4 (en) | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | |
| EP3569242A4 (en) | Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye | |
| PT3386509T (en) | Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels | |
| ZA202005891B (en) | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof | |
| HK1243351A1 (en) | Pharmaceutical composition comprising pyridopyrimidine derivative or pharmaceutically acceptable salt thereof | |
| GB2558494B (en) | Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye | |
| SG11201708692WA (en) | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof | |
| SG11202008233WA (en) | Aqueous suspension pharmaceutical preparation with controlled dissolution | |
| EP3606506A4 (en) | Methods of improving the solubility and bioavailability of therapeutic agents | |
| HK1243359A1 (en) | Pharmaceutical composition comprising bicyclo-substituted pyrazolon azo derivative or salt thereof and preparation method thereof | |
| EP3456727A4 (en) | Crystal of 3'-sialyllactose sodium salt n-hydrate, and method for producing same | |
| EP3170500A4 (en) | Prophylactic or therapeutic agent for diseases of posterior segment of eye | |
| GB201413543D0 (en) | The Game of 'Tum Tac Toe' |